FDA Grants Fast Track Designation to VX-950, an Experimental Oral Hepatitis C Virus Protease Inhibitor from (Hepatitis C Infection) Ve

FDA Grants Fast Track Designation to VX-950, an Experimental Oral Hepatitis C Virus Protease Inhibitor from Ve
HIV and Hepatitis.com - experimental oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic HCV infection. Fast Track designation indicates

24 Week Pegasys + RBV for Genotype 1: SVR predicted by week 4 response
National AIDS Treatment Advocacy Project - This analysis indicates that a treatment duration of only 24 weeks is effective in the 30% of genotype 1 and 4 patients who achieve an RVR. Thus, treatment duration might be best customized based on HCV RNA level at week 4. 2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) possible in HCV genotype 1 'super-responders'?' Preliminary results of a

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
PR Newswire - CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Vertex PharmaceuticalsIncorporated (Nasdaq: VRTX) today announced that the U.S. oral hepatitis C virus (HCV) protease inhibitor for thetreatment of HCV infection. The FDA granted